Faculty Perspectives June 2013 Vol 4 No 4 TON

This article discusses ongoing clinical investigations of the agent in a wide range of therapeutic areas.

Bendamustine is currently approved for the treatment of chronic lymphocytic leukemia (CLL), and many ongoing studies are investigating its efficacy in drug combinations.

Bendamustine has demonstrated activity as monotherapy and in combination for patients with lymphoid and hematologic as well as solid tumors.

At the 54th Annual Meeting of the American Society of Hematology, a number of abstracts were presented demonstrating the efficacy and toxicities of bendamustine either alone or in combination with other agents for the treatment of several lymphoid malignancies such as chronic lymphocytic leukemia (CLL) and indolent as well as aggressive non-Hodgkin lymphoma (NHL).